Tarsus Pharmaceuticals, Inc. (TARS) Reports Q4 Loss, Beats Revenue Estimates
Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of -5.26% and +4.63%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?